Pharma's Almanac TV
PA TV
Follow the Journey
Become a Sponsor
Current Sponsors
Avara Pharmaceutical Services
Federal Equipment Company
Globyz
Olon
Pii
Polpharma Biologics
SanaClis
SGD Pharma
TriRx Pharmaceutical Services
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Janssen Pharmaceuticals
8 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Multiple Myeloma
Janssen Reports Positive Results for DARZALEX® in Multiple Myeloma
PAO-M12-19-NI-006
FDA Approval
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PR-M10-19-NI-032
Strategic Partnership
nference Enters into an R&D Data Science Strategic Partnership with Janssen
PR-M06-19-NI-013
Drug Design
Janssen, Iktos Collaborate on In Silico Drug Design
PAO-M05-19-NI-022
FDA
Janssen Aims for Supplemental U.S. FDA Approval for INVOKANA®
PAO-M04-19-NI-007
New Drug Application
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
PR-M04-19-NI-008
HIV
Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy
PR-M03-19-NI-033
Approval
Xarelto Gets Approval for Additional Indication
PAO-M10-18-NI-019
